Brokerages Set LeMaitre Vascular, Inc. (NASDAQ:LMAT) Price Target at $95.25

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have received an average rating of “Moderate Buy” from the nine ratings firms that are covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $95.25.

Several equities analysts have weighed in on LMAT shares. Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price objective on the stock. Barrington Research downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Oppenheimer downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, Lake Street Capital increased their price target on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Friday, February 28th.

LeMaitre Vascular Stock Performance

Shares of NASDAQ:LMAT opened at $81.91 on Friday. The company has a market capitalization of $1.85 billion, a PE ratio of 44.76, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89. The stock has a fifty day moving average of $95.21 and a 200-day moving average of $94.59. LeMaitre Vascular has a one year low of $62.39 and a one year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, meeting the consensus estimate of $0.49. The business had revenue of $55.81 million during the quarter, compared to the consensus estimate of $55.99 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. As a group, research analysts forecast that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 27th. Investors of record on Thursday, March 13th will be given a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.98%. The ex-dividend date of this dividend is Thursday, March 13th. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.16. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 41.24%.

Insiders Place Their Bets

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the transaction, the insider now directly owns 5,564 shares of the company’s stock, valued at $456,915.68. This represents a 26.53 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 10.79% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in LMAT. Allspring Global Investments Holdings LLC raised its holdings in LeMaitre Vascular by 48.2% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 13,321 shares of the medical instruments supplier’s stock worth $1,227,000 after acquiring an additional 4,330 shares during the period. Townsquare Capital LLC grew its position in shares of LeMaitre Vascular by 38.0% in the third quarter. Townsquare Capital LLC now owns 47,953 shares of the medical instruments supplier’s stock valued at $4,454,000 after purchasing an additional 13,210 shares during the last quarter. Barclays PLC increased its stake in shares of LeMaitre Vascular by 394.5% in the third quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock worth $3,396,000 after purchasing an additional 29,180 shares during the period. Compass Planning Associates Inc acquired a new position in shares of LeMaitre Vascular during the 4th quarter worth about $567,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in LeMaitre Vascular by 6.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 191,511 shares of the medical instruments supplier’s stock valued at $17,789,000 after purchasing an additional 11,395 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.